Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Empagliflozin vs Ezetimibe (Zetia): Ezetimibe (Zetia) has the stronger overall evidence (4.4 vs 4.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Ezetimibe (Zetia) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Off-label use mirrors approved dosing (10–25 mg once daily in the morning) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (empagliflozin)
10 mg once daily, with or without food, alone or added to a statin — under a clinician. A prescription drug; not a self-directed supplement regimen.
any
Oral tablet (ezetimibe 10 mg)
Months to years
Months to years
Weeks to months
Throughout use
2–4 weeks
Months to years
Throughout use
Throughout use
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · Rct
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · Rct
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
The New England journal of medicine (2015) · Rct · n=18144
IMPROVE-IT randomized trial: ~18,000 patients stabilized after acute coronary syndromes
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Lancet (London, England) (2011) · Rct · n=9438
SHARP randomized placebo-controlled trial in chronic kidney disease (n≈9,400)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
The New England journal of medicine (2008) · Rct · n=1873
SEAS randomized trial in patients with mild-to-moderate aortic stenosis
Ezetimibe (Zetia) has a higher evidence score (4.4/10 vs 4.5/10) and wins in 2 of 3 categories.
For support heart health, Empagliflozin has a higher relevance score (72 vs 68).
No known interactions between Empagliflozin and Ezetimibe (Zetia) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.